Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Imaging Studies VII: Vascular Imaging01:19

Imaging Studies VII: Vascular Imaging

42
DefinitionRenal angiography, also known as renal arteriography, is an imaging technique used to obtain a comprehensive view of blood flow and the vascular structure of blood vessels in the kidneys and surrounding areas.PurposeRenal angiography detects blood vessel abnormalities in the kidneys, such as aneurysms, stenosis, thrombosis, vascular tumors, and renal artery stenosis. It evaluates kidney function and guides interventional treatments like angioplasty or stent placement.Pre-Procedure...
42
Imaging Studies II: Ultrasonography01:24

Imaging Studies II: Ultrasonography

33
IntroductionUltrasonography, or renal ultrasound, is a noninvasive medical imaging technique that uses high-frequency sound waves to visualize the kidneys, ureters, bladder, and surrounding tissues.Indications for Urinary System UltrasonographyUrinary system ultrasonography is indicated in various clinical scenarios, such as:Kidney Stones (Urolithiasis): To detect and monitor the size and presence of kidney or urinary tract stones.Hydronephrosis: To assess the dilation of the renal pelvis and...
33

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

One-Year Follow-Up of Vascular Intervention Trials Disrupted by the COVID-19 Pandemic: A Use-Case landscape.

Cardiovascular revascularization medicine : including molecular interventions·2022
Same author

Durability of blood pressure reduction after ultrasound renal denervation: three-year follow-up of the treatment arm of the randomised RADIANCE-HTN SOLO trial.

EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology·2022
Same author

Subclinical Leaflet Thrombosis and Anticoagulation After Transcatheter Aortic Valve Replacement: A Review.

JAMA cardiology·2022
Same author

Polymer-Based Versus Polymer-Free Stents in High Bleeding Risk Patients: Final 2-Year Results From Onyx ONE.

JACC. Cardiovascular interventions·2022
Same author

Efficacy and Safety Considerations With Dose-Reduced Direct Oral Anticoagulants: A Review.

JAMA cardiology·2022
Same author

Treatment Gaps in Guideline-Directed Medical Therapy for Patients Undergoing Higher-Risk Percutaneous Coronary Intervention.

Circulation. Cardiovascular interventions·2022

Related Experiment Video

Updated: Aug 8, 2025

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension
04:37

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension

Published on: June 6, 2025

216

Patient-Level Pooled Analysis of Ultrasound Renal Denervation in the Sham-Controlled RADIANCE II, RADIANCE-HTN SOLO,

Ajay J Kirtane1,2, Andrew S P Sharp3, Felix Mahfoud4,5

  • 1Columbia University Medical Center/NewYork-Presbyterian Hospital and the Cardiovascular Research Foundation, New York.

JAMA Cardiology
|February 28, 2023
PubMed
Summary
This summary is machine-generated.

Ultrasound renal denervation (uRDN) effectively lowers blood pressure (BP) in patients with hypertension (HTN). This consistent effect was observed across various severities of HTN in sham-controlled trials.

More Related Videos

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

3.4K
Reduction of Radiation Exposure during Endovascular Treatment of Peripheral Arterial Disease Combining Fiber Optic RealShape Technology and Intravascular Ultrasound
13:48

Reduction of Radiation Exposure during Endovascular Treatment of Peripheral Arterial Disease Combining Fiber Optic RealShape Technology and Intravascular Ultrasound

Published on: April 21, 2023

1.6K

Related Experiment Videos

Last Updated: Aug 8, 2025

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension
04:37

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension

Published on: June 6, 2025

216
Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

3.4K
Reduction of Radiation Exposure during Endovascular Treatment of Peripheral Arterial Disease Combining Fiber Optic RealShape Technology and Intravascular Ultrasound
13:48

Reduction of Radiation Exposure during Endovascular Treatment of Peripheral Arterial Disease Combining Fiber Optic RealShape Technology and Intravascular Ultrasound

Published on: April 21, 2023

1.6K

Area of Science:

  • Cardiovascular Medicine
  • Interventional Cardiology
  • Hypertension Management

Background:

  • Uncontrolled hypertension (HTN) poses significant cardiovascular risks.
  • Ultrasound renal denervation (uRDN) has demonstrated potential for blood pressure (BP) reduction.
  • Understanding the consistency and magnitude of uRDN's effect across the HTN spectrum is crucial for clinical application.

Purpose of the Study:

  • To evaluate the effectiveness and safety of uRDN compared to a sham procedure.
  • To analyze pooled, individual patient-level data from multiple uRDN trials.
  • To assess uRDN's impact on patients with mild-to-moderate HTN and treatment-resistant HTN.

Main Methods:

  • Pooled analysis of individual patient data from three sham-controlled uRDN trials (RADIANCE-HTN SOLO, TRIO, and RADIANCE II).
  • Standardized operational implementation, including medication and blinding protocols.
  • Comparison of baseline-adjusted change in 2-month daytime ambulatory systolic BP (dASBP) between uRDN and sham groups using linear regression.

Main Results:

  • A total of 506 patients were randomized (293 uRDN, 213 sham).
  • uRDN resulted in a significantly greater reduction in dASBP compared to sham (-5.9 mm Hg; P < .001).
  • Consistent BP reductions were observed across trials, BP parameters (ambulatory, office, home), and patient subgroups. No significant safety differences were noted.

Conclusions:

  • uRDN demonstrates consistent blood pressure-lowering effects across varying degrees of hypertension.
  • The findings support uRDN as an effective treatment option for a broad range of hypertensive patients.
  • Pooled analysis confirms the efficacy and safety of uRDN in sham-controlled settings.